Literature DB >> 25596869

Tricuspid repair at pulmonary valve replacement does not alter outcomes in tetralogy of Fallot.

Jonathan W Cramer1, Salil Ginde2, Garick D Hill1, Scott B Cohen2, Peter J Bartz2, James S Tweddell3, Michael G Earing4.   

Abstract

BACKGROUND: Chronic pulmonary regurgitation after tetralogy of Fallot repair often leads to progressive right ventricle dilation, dysfunction, and frequently, pulmonary valve replacement. For those with significant tricuspid regurgitation at the time of pulmonary valve replacement, it is unknown whether concomitant tricuspid valve repair improves postoperative outcomes.
METHODS: This is a retrospective review of patients after tetralogy of Fallot repair who underwent pulmonary valve replacement between 1999 and 2012. Preoperative and postoperative echocardiograms were assessed for tricuspid regurgitation (vena contracta) and right ventricular size and function (Tomtec software).
RESULTS: Sixty-two patients underwent pulmonary valve replacement. Thirty-six (58%) had greater than or equal to moderate tricuspid regurgitation on preoperative echocardiogram. Significant predictors were not identified. Of the 36, 18 (50%) underwent concomitant tricuspid valve repair at the time of pulmonary valve replacement. After surgery, there was a significant reduction in the degree of tricuspid regurgitation (p < 0.001) and measures of right ventricular size (p < 0.05) in both cohorts. Between surgical groups, there was no statistical difference in the grade of tricuspid regurgitation (p = 0.47) or measures of right ventricular size (p > 0.4) at 6-month follow-up.
CONCLUSIONS: Tricuspid regurgitation is a common finding in repaired tetralogy of Fallot, although risk factors for its development remain unclear. After pulmonary valve replacement with or without tricuspid valve repair there is significant improvement in the degree of tricuspid regurgitation and right ventricular size. Finally, 6 months after pulmonary valve replacement there were no statistical differences between those patients undergoing concomitant tricuspid valve repair and those undergoing pulmonary valve replacements alone.
Copyright © 2015 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25596869     DOI: 10.1016/j.athoracsur.2014.09.086

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  5 in total

Review 1.  Pulmonary valve replacement after repaired Tetralogy of Fallot.

Authors:  Hideki Tatewaki; Akira Shiose
Journal:  Gen Thorac Cardiovasc Surg       Date:  2018-05-19

2.  Tricuspid Valve Repair at Pulmonary Valve Replacement in Repaired Tetralogy of Fallot.

Authors:  Jooncheol Min; Jae Gun Kwak; Sungkyu Cho; Eung Re Kim; Jae Hong Lim; Chang-Ha Lee; Woong-Han Kim
Journal:  Pediatr Cardiol       Date:  2021-07-31       Impact factor: 1.655

Review 3.  Four-dimensional flow cardiovascular magnetic resonance in tetralogy of Fallot: a systematic review.

Authors:  Ayah Elsayed; Kathleen Gilbert; Miriam Scadeng; Brett R Cowan; Kuberan Pushparajah; Alistair A Young
Journal:  J Cardiovasc Magn Reson       Date:  2021-05-20       Impact factor: 5.364

4.  Tricuspid flow and regurgitation in congenital heart disease and pulmonary hypertension: comparison of 4D flow cardiovascular magnetic resonance and echocardiography.

Authors:  Mieke M P Driessen; Marjolijn A Schings; Gertjan Tj Sieswerda; Pieter A Doevendans; Erik H Hulzebos; Marco C Post; Repke J Snijder; Jos J M Westenberg; Arie P J van Dijk; Folkert J Meijboom; Tim Leiner
Journal:  J Cardiovasc Magn Reson       Date:  2018-01-15       Impact factor: 5.364

5.  Tricuspid Valve Intervention at the Time of Pulmonary Valve Replacement in Adults With Congenital Heart Disease: A Systematic Review and Meta-Analysis.

Authors:  Jef Van den Eynde; Connor P Callahan; Mauro Lo Rito; Nabil Hussein; Horacio Carvajal; Alvise Guariento; Arjang Ruhparwar; Alexander Weymann; Werner Budts; Marc Gewillig; Michel Pompeu Sá; Shelby Kutty
Journal:  J Am Heart Assoc       Date:  2021-12-07       Impact factor: 6.106

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.